Surrey Clinical Research Centre Signs a Five Year Agreement for OmniComm Systems'(R) Promasys(R) Software

FORT LAUDERDALE, FL--(Marketwired - Apr 14, 2014) - OmniComm Systems, Inc. (OTCQB: OMCM) a leading global provider of clinical data management solutions for clinical trials, announced the signing of a five year agreement for its Promasys investigator initiated trials (IITs) technology with Surrey Clinical Research Centre (Surrey CRC) at the University of Surrey, a UK based research center focused on the design and execution of Phase I and IIa trials in sleep, psychopharmacology, oncology, immunology and vaccines.

After a thorough evaluation process of various commercially available technologies, Surrey CRC selected Promasys technology to manage its clinical research activities. Promasys ranked highest across all categories including ease of use, fast study build, data quality and integrity and volunteer recruitment. Promasys' versatility through its mobile technology and overall functionality, as well as its lower total cost-of-ownership, was also a significant factor in the decision.

"We look forward to working with OmniComm Promasys," states Carol Stillwell, head of data management, Surrey CRC. "Having worked with several commercial technologies over the past couple of years, we were impressed by the ease of operation of the Promasys system, and with the backing of an established company such as OmniComm feel that Promasys will go from strength to strength."

Promasys will be used by Surrey CRC to support both in-house and external studies including investigator initiated trials (IITs), National Health Service (NHS) studies, and industry sponsored trials.

"We are extremely proud to have Surrey CRC as our first Promasys customer in the UK," says Wolf Ondracek, senior vice president of Academic and Asian Markets and managing director, OmniComm Promasys. "Promasys software originates from an academic environment at a top class clinical pharmacology research centre very similar to Surrey CRC. So it is a very natural fit, and it will be a pleasure for us to work closely with Surrey CRC and support them in getting the most out of our software solution."

Supporting Information

Promasys

About Surrey CRC
The Surrey CRC is a specialist clinical pharmacology unit housing 24 beds in a purpose-designed building, situated close to the Royal Surrey County Hospital. Since 1999 it has provided industry-leading services to pharmaceutical companies for Phase 1 and early Phase 2 trials in healthy subjects and patients. Surrey CRC is part of the Faculty of Health & Medical Sciences at the University of Surrey and as such provides academic and commercially sponsored early Phase trials. It has a particular expertise in sleep, psychopharmacology, oncology, immunology and vaccines. Surrey CRC is one of only two non-commercial centres which have been awarded MHRA Phase 1 Standard and Supplementary Accreditation, enabling the centre to carry out clinical trials with compounds at all levels of risk.

About OmniComm Systems
OmniComm Systems is a leading strategic software solutions provider to the life sciences industry. OmniComm Systems is dedicated to helping the world's pharmaceutical; biotechnology; contract research organizations; diagnostic and device firms; and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.

Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Trademarks
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.